CG
INFI

Cutler Group’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Cutler Group’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-200
Closed – – 4505
2023
Q2 		$0 Hold
200
– – ﹤0.01% 4387
2023
Q1 		$0 Hold
200
– – ﹤0.01% 5002
2022
Q4 		$0 Hold
200
– – ﹤0.01% 5508
2022
Q3 		$0 Sell
200
-200
-50% -$216 ﹤0.01% 5735
2022
Q2 		$0 Sell
400
-10,982
-96% -$8.43K ﹤0.01% 5927
2022
Q1 		$12K Buy
11,382
+2,100
+23% +$2.51K ﹤0.01% 3506
2021
Q4 		$20K Buy
9,282
+9,082
+4,541% +$22.8K ﹤0.01% 3142
2021
Q3 		$0 Buy
+200
New +$617 ﹤0.01% 6592
2019
Q1 		– Sell
-100
Closed – – 4946
2018
Q4 		$0 Hold
100
– – ﹤0.01% 4785
2018
Q3 		$0 Hold
100
– – ﹤0.01% 4879
2018
Q2 		$0 Hold
100
– – ﹤0.01% 5097
2018
Q1 		$0 Buy
+100
New +$214 ﹤0.01% 5452
2016
Q3 		– Sell
-800
Closed -$1K – 7569
2016
Q2 		$1K Buy
+800
New +$3.74K ﹤0.01% 6353
2016
Q1 		– Sell
-1,806
Closed -$11.1K – 7400
2015
Q4 		$14K Buy
+1,806
New +$15.5K ﹤0.01% 3803

Other funds holding INFI

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Cutler Group's INFI Position: Q3 2023 in Review

Cutler Group sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2023, closing a stake of 200 shares.

Cutler Group first reported a position in INFI in Q4 2015 and held it in 14 quarters. The position peaked at $20K in Q4 2021. 3 funds tracked by Wall St. Rank hold INFI as of Q3 2023.

  • Cutler Group reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Cutler Group sold 200 Infinity Pharmaceuticals, Inc. shares in Q3 2023.
  • Cutler Group first reported a position in Infinity Pharmaceuticals, Inc. in Q4 2015 and held it in 14 quarters.
  • Cutler Group's Infinity Pharmaceuticals, Inc. position peaked at $20K in Q4 2021.
  • 3 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2023.

Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.